Comparative Analysis of Clinical Outcomes and Healthcare Resource Utilization (HRU) in Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Unfit for High-Intensity Chemotherapy Treated with Venetoclax ( VEN) Vs Other Therapies: Results from the AML Real World Evidence (ARC) Initiative

被引：1

作者：

Desai, Pinkal ^{[1
]}

Garcia, Jacqueline S. ^{[2
]}

Zeidner, Joshua F. ^{[3
]}

Abedin, Sameem ^{[4
]}

Wolach, Ofir ^{[5
]}

Vachhani, Pankit ^{[6
]}

Moshe, Yakir ^{[7
]}

Pollyea, Daniel A. ^{[8
]}

Lai, Catherine ^{[9
]}

LeBlanc, Thomas W. ^{[10
]}

Xavier, Marin ^{[11
]}

Nachmias, Boaz ^{[12
]}

Chen, Evan C. ^{[13
]}

Bathini, Srilakshmi

Bhatti, Inderpreet ^{[14
]}

Bui, Cat N. ^{[15
]}

Guerin, Annie ^{[16
]}

Burne, Rebecca ^{[16
]}

Ma, Esprit ^{[17
]}

Grunspan, Moshe ^{[18
]}

Frankel, Neta ^{[18
]}

Goldberg, Aaron D. ^{[19
]}

机构：

[1] New York Presbyterian Hosp, Weill Cornell Med, New York, NY USA

[2] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA

[3] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA

[4] Med Coll Wisconsin, Milwaukee, WI USA

[5] Rabin Med Ctr, Petah Tiqwa, Israel

[6] Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Birmingham, AL USA

[7] Tel Aviv Sourasky Med Ctr, Div Hematol, Tel Aviv, Israel

[8] Univ Colorado, Sch Med, Aurora, CO USA

[9] Univ Penn, Abramson Canc Ctr, Philadelphia, PA USA

[10] Duke Univ, Sch Med, Div Hematol Malignancies & Cellular Therapy, Durham, NC USA

[11] Scripps Hlth, San Diego, CA USA

[12] Hebrew Univ Jerusalem, Jerusalem, Israel

[13] Dana Farber Canc Inst, Boston, MA 02115 USA

[14] Scripps MD Anderson, San Diego, CA USA

[15] AbbVie Inc, N Chicago, IL USA

[16] Anal Grp Inc, Montreal, PQ, Canada

[17] Genentech Inc, San Francisco, CA USA

[18] AbbVie Inc, Hod Hasharon, Israel

[19] Mem Sloan Kettering Canc Ctr, New York, NY USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-173283

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：6

共 10 条

[1] Comparative Effectiveness of Venetoclax Combinations Vs Other Therapies Among Patients with Newly Diagnosed Acute Myeloid Leukemia: Results from the AML Real World Evidence (ARC) Initiative
Garcia, Jacqueline S.
Wolach, Ofir
Vachhani, Pankit
Zeidner, Joshua F.
Talati, Chetasi
Pollyea, Daniel A.
Lai, Catherine
Moshe, Yakir
Abedin, Sameem
Lavie, David
Zuckerman, Tsila
Xavier, Marin
Lee, Sangmin
Edwards, Wesleigh
Chen, Evan
Bui, Cat N.
Svensson, Anders
Burne, Rebecca
Kye, Steve
Maitland, Jessica
Ma, Esprit
Montez, Melissa
Grunspan, Moshe
Goldberg, Aaron D.
BLOOD, 2021, 138
[2] Characteristics and Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Receiving Venetoclax Combinations Vs Other Therapies: Results from the AML Real World Evidence (ARC) Initiative
Pollyea, Daniel A.
Stahl, Maximilian
Talati, Chetasi
Asghari, Hannah
Lai, Catherine
Abedin, Sameem
Zeidner, Joshua F.
Muluneh, Benyam
Xavier, Marin
Edwards, Wesleigh
Wolach, Ofir
Moshe, Yakir
Lavie, David
Zuckerman, Tsila
Choi, Michelle
Bui, Cat N.
Svensson, Anders Erik
Kye, Steve
Burne, Rebecca
Guerin, Annie
Ma, Esprit
Montez, Melissa
Goldberg, Aaron D.
BLOOD, 2020, 136
[3] Comparison of Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated with Venetoclax and Hypomethylating Agents Vs Other Therapies By TP53 and IDH1/2 Mutation: Results from the AML Real World Evidence (ARC) Initiative
Wolach, Ofir
Garcia, Jacqueline S.
Desai, Pinkal
Vachhani, Pankit
Zeidner, Joshua F.
Abedin, Sameem
Sweet, Kendra
Lai, Catherine
Moshe, Yakir
Pollyea, Daniel A.
Xavier, Marin
Nachmias, Boaz
Zuckerman, Tsila
Lee, Sangmin
Chen, Evan C.
Bathini, Srilakshmi
Edwards, Wesleigh
Bui, Cat N.
Cheng, Wei-Han
Miller, Catherine
Guerin, Annie
Maitland, Jessica
Ma, Esprit
Montez, Melissa
Grunspan, Moshe
Goldberg, Aaron D.
BLOOD, 2022, 140 : 11026 - 11028
[4] Real-World Management of Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax-Based Regimens: Results from the AML Real World Evidence (ARC) Initiative
Vachhani, Pankit
Wolach, Ofir
Garcia, Jacqueline S.
Zeidner, Joshua F.
Talati, Chetasi
Pollyea, Daniel A.
Lai, Catherine
Moshe, Yakir
Abedin, Sameem
Lavie, David
Zuckerman, Tsila
Xavier, Marin
Lee, Sangmin
Chen, Evan
Edwards, Wesleigh
Bui, Cat N.
Svensson, Anders
Kye, Steve
Burne, Rebecca
Maitland, Jessica
Ma, Esprit
Montez, Melissa
Grunspan, Moshe
Goldberg, Aaron D.
BLOOD, 2021, 138
[5] Healthcare Resource Utilization (HCRU) in Patients (pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated in the Connect® MDS/AML Disease Registry
Mukherjee, Sudipto
Abedi, Mehrdad
Erba, Harry P.
Pollyea, Daniel A.
Roboz, Gail J.
Thompson, Michael A.
Louis, Chrystal U.
Flick, E. Dawn
Nifenecker, Melissa
Kiselev, Pavel
Swern, Arlene S.
Cogle, Christopher R.
BLOOD, 2018, 132
[6] Real World Data on Clinical Outcomes of Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Treated With Hypomethylating Agents (HMA) Plus Shorter Duration of Venetoclax (VEN) at a General Hospital
Khan, Hina
Yohannan, Binoy
Cervoni-Curet, Frances
Rios, Adan
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S262 - S262
[7] Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML
Daver, Naval
Senapati, Jayastu
Maiti, Abhishek
Loghavi, Sanam
Kadia, Tapan M.
DiNardo, Courtney D.
Pemmaraju, Naveen
Jabbour, Elias
Montalban-Bravo, Guillermo
Tang, Guilin
Sasaki, Koji
Borthakur, Gautam
Yilmaz, Musa
Alvarez, Joie
Pierce, Sherry A.
Gonzalez, Graciela M. Nogueras
Ning, Jing
Issa, Ghayas C.
Andreeff, Michael
Abbas, Hussein A.
Ravandi, Farhad
Garcia-Manero, Guillermo
Kantarjian, Hagop
BLOOD, 2022, 140
[8] A Retrospective Observational Real-World Study of the Characteristics, Genomic Analysis, Treatment Patterns and Outcomes of Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) in the United States
Byrd, John C.
Gatz, Jennifer L.
Cripe, Larry D.
Louis, Cynthia Lim
Mims, Alice S.
Borate, Uma
Yocum, Ashley O.
Gana, Theophilus
Burd, Amy
BLOOD, 2021, 138
[9] Phase 1b/2 Study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High Risk Acute Myeloid Leukemia (AML) and Relapsed Refractory (R/R) AML: Final Clinical Data and Genomic Markers of Resistance/Relapse
Arora, Sankalp
Senapati, Jayastu
Loghavi, Sanam
Reville, Patrick K.
Wang, Bofei
Kadia, Tapan M.
Dinardo, Courtney D.
Pemmaraju, Naveen
Yilmaz, Musa
Jabbour, Joseph E.
Short, Nicholas J.
Montalban-Bravo, Guillermo
Maiti, Abhishek
Tang, Guilin
Sasaki, Koji
Borthakur, Gautam
Alvarez, Joie
Pierce, Sherry
Gonzalez, Graciela M. Nogueras
Ning, Jing
Issa, Ghayas C.
Andreeff, Michael
Ravandi, Farhad
Garcia-Manero, Guillermo
Abbas, Hussein A.
Daver, Naval
BLOOD, 2024, 144 : 736 - 737
[10] Outcomes of Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) and TP53 mutation/Loss Treated on the Phase 2 Study of Venetoclax (Ven) Added to Alternating Cladribine (Clad) Plus Low-Dose Cytarabine (LDAC) and Azacitidine (Aza): A Subgroup Analysis
Senapati, Jayastu
Loghavi, Sanam
Reville, Patrick K.
Daver, Naval
Borthakur, Gautam
DiNardo, Courtney D.
Jabbour, Elias
Short, Nicholas J.
Pemmaraju, Naveen
Maiti, Abhishek
Issa, Ghayas C.
Popat, Uday R.
Alousi, Amin
Shpall, Elizabeth J.
Sasaki, Koji
Garcia-Manero, Guillermo
Ravandi, Farhad
Kadia, Tapan M.
BLOOD, 2023, 142

← 1 →